Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 vs Sugemalimab consolidation in Stage III NSCLC
NCT06617416Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cadonilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Progression-Free Survival at 3 years. Started Nov 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06617416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617416.